Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
RNA interference (RNAi)
Biotech
Roche continues RNA return with $1.7B deal for Sanegene drug
Roche is continuing its return to the RNAi space by paying $200 million for the worldwide license to one of SanegeneBio’s programs.
James Waldron
Feb 2, 2026 8:35am
Irish biotech launches with $21M to shuttle RNAi meds to brain
Oct 1, 2025 10:34am
Corsera launches with $50M for predictive AI tool, RNAi asset
Sep 2, 2025 6:30am
Federal mRNA vax grant cuts includes unrelated project
Aug 7, 2025 2:20pm
Sanofi pens $395M China pact for Arrowhead metabolic med
Aug 1, 2025 7:21am
Arrowhead reassures investors about pact with troubled Sarepta
Jul 23, 2025 10:13am
